Phibro Animal Health Corporation financials

PAHC CIK 0001069899

Source: EDGAR filings · Built 2026-06-19T01:23:37Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow 41.83M 46.36M -38.48M -5.39M 18.99M 25.30M
EBITDA 156.07M 89.49M 105.86M 111.69M 106.75M 101.53M
Working Capital 517.13M 396.85M 409.72M 375.40M 334.79M 294.60M
Net Debt 606.51M 278.85M 327.69M 251.24M 282.53M 206.12M
Gross Margin 30.85% 30.77% 30.50% 30.29% 32.56% 32.10%
Operating Margin 8.52% 5.24% 7.35% 8.38% 8.98% 8.65%
Net Margin 3.72% 0.24% 3.33% 5.22% 6.53% 4.19%
Return on Equity (ROE) 16.89% 0.94% 11.54% 18.74% 22.80% 17.83%
Return on Assets (ROA) 3.55% 0.25% 3.36% 5.28% 6.46% 4.28%
Current Ratio 2.76× 2.94× 3.33× 2.97× 3.04× 2.87×
Debt-to-Equity 2.36× 1.36× 1.31× 1.24× 1.40× 1.29×
Effective Tax Rate 29.02% 77.87% 39.70% 32.01% 18.18% 39.56%
Cash Conversion Ratio 1.66× 36.26× 0.41× 0.64× 0.89× 1.77×
Accruals Ratio -0.02× -0.09× 0.02× 0.02× 0.01× -0.03×
SBC % of Revenue 0.06% 0.05% 0.14% 0.28%
CapEx Coverage 2.09× 2.12× 0.26× 0.85× 1.65× 1.74×
Free Cash Flow Per Share $1.03 $1.14 $-0.95 $-0.13 $0.47 $0.62

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 1.30B 1.02B 977.89M 942.26M 833.35M 800.35M
Revenues 833.35M 800.35M
Cost of Goods and Services Sold 896.27M 704.59M 679.65M 656.86M 561.97M 543.47M
Gross Profit 399.94M 313.09M 298.24M 285.40M 271.38M 256.88M
Research and Development Expense 23.73M 29.19M 24.39M 20.83M 17.76M 13.74M
Selling, General and Administrative Expense 289.48M 259.78M 226.39M 206.41M 196.51M 187.69M
Operating Income (Loss) 110.47M 53.31M 71.85M 78.99M 74.87M 69.19M
Income Tax Expense (Benefit) 19.73M 8.50M 21.46M 23.15M 12.08M 21.96M
Net Income (Loss) Attributable to Parent 48.26M 2.42M 32.61M 49.17M 54.38M 33.55M
Earnings Per Share, Basic $1.19 $0.06 $0.81 $1.21 $1.34 $0.83
Weighted Average Number of Shares Outstanding, Basic 40.52M 40.50M 40.50M 40.50M 40.47M 40.45M
Earnings Per Share, Diluted $1.19 $0.06 $0.81 $1.21 $1.34 $0.83
Weighted Average Number of Shares Outstanding, Diluted 40.68M 40.52M 40.50M 40.50M 40.50M 40.50M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 68.04M 70.61M 41.28M 74.25M 50.21M 36.34M
Assets, Current 810.61M 601.00M 585.72M 566.23M 498.91M 451.84M
Assets 1.36B 982.18M 971.40M 931.70M 841.33M 784.10M
Long-term Debt 631.68M 312.08M 333.84M 287.93M
Liabilities, Current 293.47M 204.15M 176.00M 190.83M 164.12M 157.24M
Long-term Debt, Excluding Current Maturities 615.43M 282.29M 311.54M 272.93M
Liabilities 1.08B 725.54M 688.89M 669.26M 602.80M 595.90M
Stockholders' Equity Attributable to Parent 285.68M 256.64M 282.51M 262.44M 238.53M 188.20M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 80.12M 87.59M 13.31M 31.65M 48.31M 59.35M
Net Cash Provided by (Used in) Investing Activities -288.69M -48.19M -74.02M -22.58M -18.58M -120.39M
Payments of Dividends 19.43M 19.42M
Net Cash Provided by (Used in) Financing Activities 207.13M -6.77M 26.99M 16.34M -17.00M 40.94M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (PAHC CIK 0001069899), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

SEAT

Vivid Seats Inc.

BIXT

BIOXYTRAN, INC.

INSM

INSMED INCORPORATED